Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 43

recruiting
3 970
countries
28
conditions
2 124

10 522 trials match your criteria

Study of melpida with drug combination in patients with Hereditary Spastic Paraplegia Type 50 (SPG50)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years
  • Substances:Codeine Phosphate

Safety and Pharmacokinetic Dose-Escalation Study of IMC-S118AI and Sodium Chloride in HLA‑A*02:01‑Positive Participants with Type 1 Diabetes

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:IMC S118AI

A study of hydroxyurea added to standard drug combination to assess safety and effectiveness in adults with relapsed or refractory acute myeloid leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine

Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Asthma

Recruiting

Efficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Depemokimab

Infertility female+1

Recruiting

Study of Follitropin Delta, Triptorelin and Choriogonadotropin Alfa for Ovulation Trigger in IVF with Fresh Transfer in Women with Low Ovarian Reserve

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Follitropin Delta

A Study to Assess Safety and Efficacy of Surzetoclax Alone or with Etentamig in Adults with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Etentamig

COVID-19

Recruiting

Study of nirmatrelvir and remdesivir to achieve viral clearance in immunocompromised patients with persistent COVID-19

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nirmatrelvir

Endometriosis

Recruiting

PET Imaging with [18F]AlF-FAPI-74 and Hyoscine Butylbromide in Patients Suspected of Endometriosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:[Al[18F]F]Fapi-74

Indapamide for Reducing Disability Progression in Adults with Primary and Secondary Progressive Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Indapamide hemihydrate

Phase 2 Study of ALN-6400 Safety and Tolerability in Female Patients with Von Willebrand Disease and Heavy Menstrual Bleeding

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Pexamsiran

A Phase 2a Study of Empasiprubart IV Monotherapy in Adults with AChR‑Ab Seropositive Generalized Myasthenia Gravis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.